Trial Profile
A Randomized Phase 2/3 Study of DACOGEN (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Talacotuzumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 20 Dec 2022 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 01 Jan 2021 Primary endpoint (Overall Survival) has not been met.
- 01 Jan 2021 Primary endpoint (Complete Response Rate) has not been met.